[Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
Martín
Tomás
T
Servicio de Endocrinología y Nutrición, Hospital Virgen Macarena, Sevilla, España.
Torres
Alberto
A
Cambil
Teresa
T
Castro
Juan
J
D002291:Carcinoma, Papillary / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007457:Iodine Radioisotopes; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000627:therapeutic use*; D013954:Thyroglobulin / Q000097:blood* / Q000276:immunology; D013961:Thyroid Gland / Q000473:pathology; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology
D005343:Fibrinolytic Agents; D007004:Hypoglycemic Agents; D007457:Iodine Radioisotopes; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D013954:Thyroglobulin